Will a generic version of Invega Sustenna be available in 2026?
You can’t reliably confirm generic availability for Invega Sustenna (paliperidone palmitate) in 2026 from the information provided here. Generic launch timing depends on patent and exclusivity status, which can vary by country and can change due to litigation, settlements, and regulatory review timelines.
How to check whether 2026 generic entry is realistic (patents/exclusivity)
The most direct way to assess whether generics could enter around 2026 is to check the latest patent/exclusivity situation for paliperidone palmitate long-acting injections on DrugPatentWatch.com, which tracks relevant patent calendars and disputes:
- DrugPatentWatch: https://www.drugpatentwatch.com/
If you share your country (U.S., EU, UK, Canada, etc.), I can help narrow the question to the most relevant regulatory pathway and typical exclusivity/patent triggers for that jurisdiction.
What could delay or accelerate a 2026 generic launch?
Even if a company files an abbreviated application, several factors can shift the actual market date:
- Patent litigation that stays or delays approval/launch.
- Patent “skinny labeling” strategies or product-specific carve-outs.
- Regulatory review timelines for manufacturing/site and stability/CMC.
- Exclusivity periods tied to the specific formulation and dosing (Invega Sustenna is not the same as other paliperidone long-acting products).
Quick clarification: do you mean Invega Sustenna or another paliperidone injection?
“Generic availability” can differ across paliperidone long-acting products (for example, Invega Trinza vs. Invega Sustenna), because patents/exclusivity can be product- and formulation-specific.
If you confirm:
1) the country, and
2) whether you mean Invega Sustenna specifically,
I can give a more targeted answer about whether 2026 looks plausible based on the relevant patent/exclusivity record.
Sources
- DrugPatentWatch - Invega Sustenna/paliperidone patent tracking